Trials / Completed
CompletedNCT04494243
A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
A Randomized, Open-label, Multiple-dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in healthy volunteers.
Detailed description
This study is to compare the safety, pharmacokinetic characteristics and pharmacodynamics characteristics of AD-214 10/600mg compared with administration of Rabeprazole 10mg in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-214 10/600mg | 1 tablet administered before the breakfast during 7 days |
| DRUG | Rabeprazole 10mg | 1 tablet administered before the breakfast during 7 days |
Timeline
- Start date
- 2020-08-28
- Primary completion
- 2021-01-15
- Completion
- 2021-01-15
- First posted
- 2020-07-31
- Last updated
- 2021-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04494243. Inclusion in this directory is not an endorsement.